Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 2004

View Archived Issues

No difference in risks with tamoxifen use between African American and white breast cancer patients

Significant relief achieved with octreotide in cluster headache patients

Novel PDE5 inhibitor from Fujisawa

Aromatase inhibitor reduces seizure rate in male patients with partial epilepsy

Clinical benefits of liposteroid therapy in West syndrome patients

Significant pain relief achieved with levetiracetam in trigeminal neuralgia

Improved glycemic control achieved with insulin glulisine in type 2 diabetes

Enrollment completed in SAINT I study of Cerovive in stroke patients

Wyeth responds to U.K. MHRA's action on Efexor

U.S. launch of DepoDur

Myriad files IND for phase I study of MPC-6827

Serono and Micromet sign collaboration and license agreement for MT-201

FAST phase II/III study completed for Fibrillex

Recordati seeks German approval of fixed combination product for hypertension

Intravenous Boniva submitted for FDA approval

Swiss clearance for phase I study of 1D09C3

Nabi eyes StaphVAX filings in Europe and U.S.

Topigen to conduct pilot study of potential asthma treatment ASM-8

PTC-124 awarded orphan drug status for cystic fibrosis

Immune Response Corporation expands MS development program

Final phase II results confirm the efficacy of telavancin in cSSSI

Enrollment open in phase Ib study of ARQ-501 and Taxotere

Update on the safety and antiepileptic effects of UCB-34714

Enrollment under way in pivotal MS study of MBP-8298

Palatin reports new agents for the treatment of obesity

Novel opioid receptor antagonists emerge from Pfizer R&D

Dabur researchers describe anticancer compounds

Janssen claims antiinflammatory phospholipase C inhibitors in patent

New beta-lactamase inhibitors designed by Wyeth researchers

Roche claims CRF receptor antagonists and their use in stress-related disorders, anxiety, etc.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...